AngioDynamics, Inc. (ANGO): Price and Financial Metrics
ANGO Price/Volume Stats
Current price | $5.39 | 52-week high | $12.62 |
Prev. close | $5.37 | 52-week low | $5.26 |
Day low | $5.27 | Volume | 532,700 |
Day high | $5.54 | Avg. volume | 532,217 |
50-day MA | $5.89 | Dividend yield | N/A |
200-day MA | $7.51 | Market Cap | 214.82M |
ANGO Stock Price Chart Interactive Chart >
ANGO POWR Grades
- Value is the dimension where ANGO ranks best; there it ranks ahead of 87.41% of US stocks.
- ANGO's strongest trending metric is Growth; it's been moving down over the last 26 weeks.
- ANGO ranks lowest in Momentum; there it ranks in the 24th percentile.
ANGO Stock Summary
- The ratio of debt to operating expenses for ANGIODYNAMICS INC is higher than it is for about just 0.22% of US stocks.
- With a year-over-year growth in debt of -100%, ANGIODYNAMICS INC's debt growth rate surpasses merely 0% of about US stocks.
- Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for ANGO comes in at 15.75% -- higher than that of 89.4% of stocks in our set.
- If you're looking for stocks that are quantitatively similar to ANGIODYNAMICS INC, a group of peers worth examining would be CSPI, GGG, PLAB, ALOT, and ITT.
- Visit ANGO's SEC page to see the company's official filings. To visit the company's web site, go to www.angiodynamics.com.
ANGO Valuation Summary
- ANGO's EV/EBIT ratio is -72.4; this is 595.89% lower than that of the median Healthcare stock.
- ANGO's EV/EBIT ratio has moved down 112 over the prior 238 months.
Below are key valuation metrics over time for ANGO.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
ANGO | 2023-12-29 | 0.9 | 0.7 | 48.5 | -72.4 |
ANGO | 2023-12-28 | 0.9 | 0.7 | 49.4 | -74.2 |
ANGO | 2023-12-27 | 1.0 | 0.7 | 49.7 | -74.7 |
ANGO | 2023-12-26 | 0.9 | 0.7 | 49.3 | -73.9 |
ANGO | 2023-12-22 | 0.9 | 0.7 | 49.2 | -73.8 |
ANGO | 2023-12-21 | 0.9 | 0.7 | 48.0 | -71.7 |
ANGO Growth Metrics
- The 3 year revenue growth rate now stands at -12.93%.
- The 4 year net income to common stockholders growth rate now stands at 295.21%.
- Its year over year cash and equivalents growth rate is now at -56.14%.
The table below shows ANGO's growth in key financial areas (numbers in millions of US dollars).
Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
---|---|---|---|
2022-12-31 | 327.934 | -17.477 | -32.714 |
2022-09-30 | 320.785 | -23.035 | -32.579 |
2022-06-30 | 316.219 | -7.194 | -26.547 |
2022-03-31 | 306.063 | -3.555 | -39.749 |
2021-12-31 | 303.275 | 11.107 | -38.335 |
2021-09-30 | 297.765 | 20.614 | -34.252 |
ANGO's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- ANGO has a Quality Grade of D, ranking ahead of 15.86% of graded US stocks.
- ANGO's asset turnover comes in at 0.521 -- ranking 88th of 186 Medical Equipment stocks.
- CLPT, EW, and IVC are the stocks whose asset turnover ratios are most correlated with ANGO.
The table below shows ANGO's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-08-31 | 0.521 | 0.541 | -0.324 |
2021-05-31 | 0.503 | 0.539 | -0.282 |
2021-02-28 | 0.464 | 0.531 | -1.297 |
2020-11-30 | 0.434 | 0.540 | -1.344 |
2020-08-31 | 0.407 | 0.551 | -1.516 |
2020-05-31 | 0.385 | 0.569 | -1.758 |
ANGO Price Target
For more insight on analysts targets of ANGO, see our ANGO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
Average Price Target | $30.00 | Average Broker Recommendation | 1.5 (Moderate Buy) |
AngioDynamics, Inc. (ANGO) Company Bio
AngioDynamics designs, manufactures, and sells various medical, surgical, and diagnostic devices for vascular access, surgery, peripheral vascular disease, and oncology in the United States and internationally. The company was founded in 1988 and is based in Latham, New York.
Latest ANGO News From Around the Web
Below are the latest news stories about ANGIODYNAMICS INC that investors may wish to consider to help them evaluate ANGO as an investment opportunity.
AngioDynamics to Present at the J.P. Morgan Healthcare ConferenceLATHAM, N.Y., December 21, 2023--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients, today announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will present at the J.P. Morgan 42nd Annual Healthcare Conference at 9:00 |
Why AngioDynamics (ANGO) Outpaced the Stock Market TodayThe latest trading day saw AngioDynamics (ANGO) settling at $7.63, representing a +1.87% change from its previous close. |
AngioDynamics (ANGO) Stock Drops Despite Market Gains: Important Facts to NoteAngioDynamics (ANGO) closed at $6.91 in the latest trading session, marking a -0.72% move from the prior day. |
AngioDynamics to Report Fiscal 2024 Second Quarter Financial Results on January 5, 2024LATHAM, N.Y., December 07, 2023--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients, today announced that it will report financial results for the second quarter of fiscal year 2024 before the market open on Friday, January 5, 2024. The Company’s management will host a conference call at 8:00 a.m. ET the same |
AngioDynamics Completes Patient Enrollment in APEX-AV Study Assessing AlphaVac F1885 System in Treatment of Pulmonary EmbolismLATHAM, N.Y., December 07, 2023--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced the completion of patient enrollment in the Acute Pulmonary Embolism Extraction Trial with the AlphaVac System (APEX-AV). APEX-AV is a clinical study aimed at evaluating the safety and efficacy of the Company’s Alp |
ANGO Price Returns
1-mo | -12.92% |
3-mo | -28.42% |
6-mo | -24.19% |
1-year | -56.00% |
3-year | -74.72% |
5-year | -75.84% |
YTD | -31.25% |
2023 | -43.06% |
2022 | -50.07% |
2021 | 79.91% |
2020 | -4.25% |
2019 | -20.47% |
Continue Researching ANGO
Want to do more research on Angiodynamics Inc's stock and its price? Try the links below:Angiodynamics Inc (ANGO) Stock Price | Nasdaq
Angiodynamics Inc (ANGO) Stock Quote, History and News - Yahoo Finance
Angiodynamics Inc (ANGO) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...